- Home
- REVBW vs NYMTL Comparison
REVBW vs NYMTL Comparison
Compare REVBW & NYMTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- NYMTL
- Stock Information
- Founded
- REVBW N/A
- NYMTL N/A
- Country
- REVBW United States
- NYMTL United States
- Employees
- REVBW 9
- NYMTL 79
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- NYMTL Real Estate Investment Trusts
- Sector
- REVBW Health Care
- NYMTL Real Estate
- Exchange
- REVBW Nasdaq
- NYMTL Nasdaq
- Market Cap
- REVBW N/A
- NYMTL N/A
- IPO Year
- REVBW 2020
- NYMTL N/A
- Fundamental
- Price
- REVBW $0.02
- NYMTL $21.55
- Analyst Decision
- REVBW
- NYMTL
- Analyst Count
- REVBW 0
- NYMTL 0
- Target Price
- REVBW N/A
- NYMTL N/A
- AVG Volume (30 Days)
- REVBW N/A
- NYMTL N/A
- Earning Date
- REVBW N/A
- NYMTL N/A
- Dividend Yield
- REVBW N/A
- NYMTL N/A
- EPS Growth
- REVBW N/A
- NYMTL N/A
- EPS
- REVBW N/A
- NYMTL N/A
- Revenue
- REVBW N/A
- NYMTL N/A
- Revenue This Year
- REVBW N/A
- NYMTL N/A
- Revenue Next Year
- REVBW N/A
- NYMTL N/A
- P/E Ratio
- REVBW N/A
- NYMTL N/A
- Revenue Growth
- REVBW N/A
- NYMTL N/A
- 52 Week Low
- REVBW N/A
- NYMTL N/A
- 52 Week High
- REVBW N/A
- NYMTL N/A
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- NYMTL 35.45
- Support Level
- REVBW N/A
- NYMTL $21.97
- Resistance Level
- REVBW N/A
- NYMTL $22.30
- Average True Range (ATR)
- REVBW 0.00
- NYMTL 0.25
- MACD
- REVBW 0.00
- NYMTL -0.05
- Stochastic Oscillator
- REVBW 0.00
- NYMTL 5.56
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About NYMTL New York Mortgage Trust Inc. 6.875% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock $0.01 par value per share
New York Mortgage Trust Inc is a real estate investment trust for federal income tax purposes, in the business of acquiring, investing in, financing and managing mortgage-related and residential housing-related assets. The company's investment portfolio consists of Structured multi-family property investments such as multi-family CMBS an preferred equity in, and mezzanine loans to owners of multi-family properties. Distressed residential assets such as residential mortgage loans sourced from distressed markets and non-Agency RMBS. Second mortgages, Agency RMBS, and certain other mortgage-related and residential housing-related assets.